These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 20502137)

  • 1. Amisulpride monotherapy in a patient with clozapine-resistant schizophrenia.
    Pehlivanidis A; Spyropoulou AC; Tourkantonis A; Papadimitriou GN
    Clin Neuropharmacol; 2010 May; 33(3):168. PubMed ID: 20502137
    [No Abstract]   [Full Text] [Related]  

  • 2. Amisulpride treatment for clozapine-induced sialorrhea.
    Praharaj SK; Sarkar S; Sinha VK
    J Clin Psychopharmacol; 2009 Apr; 29(2):189-90. PubMed ID: 19512987
    [No Abstract]   [Full Text] [Related]  

  • 3. The 5-HT2 receptor profiles of antipsychotics in the pathogenesis of obsessive-compulsive symptoms in schizophrenia.
    Kim SW; Shin IS; Kim JM; Youn T; Yang SJ; Hwang MY; Yoon JS
    Clin Neuropharmacol; 2009; 32(4):224-6. PubMed ID: 19644229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frontal fasciculi and psychotic symptoms in antipsychotic-naive patients with schizophrenia before and after 6 weeks of selective dopamine D2/3 receptor blockade.
    Ebdrup BH; Raghava JM; Nielsen MØ; Rostrup E; Glenthøj B
    J Psychiatry Neurosci; 2016 Mar; 41(2):133-41. PubMed ID: 26599135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity.
    Schoemaker H; Claustre Y; Fage D; Rouquier L; Chergui K; Curet O; Oblin A; Gonon F; Carter C; Benavides J; Scatton B
    J Pharmacol Exp Ther; 1997 Jan; 280(1):83-97. PubMed ID: 8996185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amisulpride a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials.
    Leucht S
    Int J Neuropsychopharmacol; 2004 Mar; 7 Suppl 1():S15-20. PubMed ID: 14972080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity.
    Perrault G; Depoortere R; Morel E; Sanger DJ; Scatton B
    J Pharmacol Exp Ther; 1997 Jan; 280(1):73-82. PubMed ID: 8996184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of clozapine and amisulpride in treatment-resistant schizophrenia--case reports and review of the literature.
    Zink M; Knopf U; Henn FA; Thome J
    Pharmacopsychiatry; 2004 Jan; 37(1):26-31. PubMed ID: 14750045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cariprazine, an orally active D2/D3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depression.
    Gründer G
    Curr Opin Investig Drugs; 2010 Jul; 11(7):823-32. PubMed ID: 20571978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopamine D3 and D4 receptor antagonists in the treatment of schizophrenia.
    Jardemark K; Wadenberg ML; Grillner P; Svensson TH
    Curr Opin Investig Drugs; 2002 Jan; 3(1):101-5. PubMed ID: 12054059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Schizophrenia.
    Freedman R
    N Engl J Med; 2003 Oct; 349(18):1738-49. PubMed ID: 14585943
    [No Abstract]   [Full Text] [Related]  

  • 12. Combined treatment with amisulpride in patients with schizophrenia discharged from a short-term hospitalization unit: a 1-year retrospective study.
    Molina JD; Lerma-Carrillo I; Leonor M; Pascual F; Blasco-Fontecilla H; González-Parra S; López-Muñoz F; Alamo C
    Clin Neuropharmacol; 2009; 32(1):10-5. PubMed ID: 18978498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Augmentation of clozapine with amisulpride: a promising therapeutic approach to refractory schizophrenic symptoms.
    Kämpf P; Agelink MW; Naber D
    Pharmacopsychiatry; 2005 Jan; 38(1):39-40. PubMed ID: 15706467
    [No Abstract]   [Full Text] [Related]  

  • 14. Quetiapine combined with amisulpride in schizophrenic patients with insufficient responses to quetiapine monotherapy.
    Englisch S; Enning F; Grosshans M; Marquardt L; Waltereit R; Zink M
    Clin Neuropharmacol; 2010; 33(5):227-9. PubMed ID: 20838213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amisulpride improved debilitating clozapine-induced sialorrhea.
    Praharaj SK; Ray P; Gandotra S
    Am J Ther; 2011 May; 18(3):e84-5. PubMed ID: 20068443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clozapine and amisulpride in refractory schizophrenia and alcohol dependence.
    Dervaux A; Cazali J
    J Clin Psychopharmacol; 2007 Oct; 27(5):514-6. PubMed ID: 17873688
    [No Abstract]   [Full Text] [Related]  

  • 17. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial.
    Assion HJ; Reinbold H; Lemanski S; Basilowski M; Juckel G
    Pharmacopsychiatry; 2008 Jan; 41(1):24-8. PubMed ID: 18203048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined use of amisulpride and clozapine for patients with treatment-resistant schizophrenia.
    Cook B; Hoogenboom G
    Australas Psychiatry; 2004 Mar; 12(1):74-6. PubMed ID: 15715745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is amisulpride an 'atypical' atypical antipsychotic agent?
    Lecrubier Y
    Int Clin Psychopharmacol; 2000 Dec; 15 Suppl 4():S21-6. PubMed ID: 11252520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DRD2 genotypic and haplotype variation is associated with improvements in negative symptoms after 6 weeks' amisulpride treatment.
    Kang SG; Na KS; Lee HJ; Chee IS; Lee K; Lee J
    J Clin Psychopharmacol; 2015 Apr; 35(2):158-62. PubMed ID: 25679126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.